Oryon Cell Therapies, a biotech company developing Parkinson’s cell therapy, has made three significant announcements on its first day trading. The key move is the hiring of Ron Cohen as its new CEO. Cohen previously led Acorda Therapeutics, another pharmaceutical company focused on treating neurological disorders. With this change, Oryon aims to advance its stem cell therapy for Parkinson’s disease, a goal that has been in development since the company’s inception.
Source: https://endpoints.news/former-acorda-ceo-ron-cohen-emerges-at-parkinsons-cell-therapy-biotech-oryon